Pharmaceuticals 2010, 3(8), 2441-2469; doi:10.3390/ph3082441
Review

Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies

Roswell Park Cancer Institute, Genitourinary Program, Grace Cancer Drug Center, Buffalo, NY 14263, USA
* Author to whom correspondence should be addressed.
Received: 16 July 2010; in revised form: 30 July 2010 / Accepted: 2 August 2010 / Published: 4 August 2010
(This article belongs to the Special Issue HDAC Inhibitors)
PDF Full-text Download PDF Full-Text [413 KB, uploaded 4 August 2010 12:25 CEST]
Abstract: Advancement in the understanding of cancer development in recent years has identified epigenetic abnormalities as a common factor in both tumorigenesis and refractory disease. One such event is the dysregulation of histone deacetylases (HDACs) in both hematological and solid tumors, and has consequently resulted in the development of HDAC inhibitors (HDACI) to overcome this. HDACI exhibit pleiotropic biological effects including inhibition of angiogenesis and the induction of autophagy and apoptosis. Although HDACI exhibit modest results as single agents in preclinical and clinical data, they often fall short, and therefore HDACI are most promising in combinational strategies with either standard treatments or with other experimental chemotherapies and targeted therapies. This review will discuss the induction of autophagy and apoptosis and the inhibition of angiogenesis by HDACI, and also pre-clinical and clinical combination strategies using these agents.
Keywords: cancer; epigenetics; epigenetic therapy; HDAC; HDAC inhibitors; apoptosis; angiogenesis; autophagy; pre-clinical; clinical trial

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Ellis, L.; Pili, R. Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies. Pharmaceuticals 2010, 3, 2441-2469.

AMA Style

Ellis L, Pili R. Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies. Pharmaceuticals. 2010; 3(8):2441-2469.

Chicago/Turabian Style

Ellis, Leigh; Pili, Roberto. 2010. "Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies." Pharmaceuticals 3, no. 8: 2441-2469.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert